Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Muhamed Baljevic, Nizar J. Bahlis, Rami Kotb, Gary J. Schiller, Brea Lipe, Sumit Madan, Heather J. Sutherland, Suzanne Lentzsch, Natalie Callander, Noa Biran, Dane Van Domelen, Tomer Mark, Darrell White

Blood (2024) 144 (Supplement 1): 1996.

https://doi.org/10.1182/blood-2024-208086

Published: 2024

Journal Articles

Selinexor Disrupts Epigenetic Programing and Modulates Immunogenicity in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3301.

https://doi.org/10.1182/blood-2023-190658

Published: 2023

Journal Articles

Real World Observational Study Using Clonoseq® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry

Krish Patel, MD, Neil Bailey, MSc, Cristina J. Gasparetto, MD, Tomer Mark, MD MSc, Bijal Shah, MD, Jakub Svoboda, MD, Michael A. Thompson, MD PhD, Heidi Simmons, PhD, Mark Schliekelman, PhD, Allison P. Jacob, Lance Baldo, MD, John M. Pagel, MDPhD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-141440

Published: 2020

Journal Articles

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Shaji Kumar, MD, Meletios A Dimopoulos, Efstathios Kastritis, MD, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, MD, Jens Hillengass, MD, Xavier Leleu, Meral Beksac, MD, Melissa Alsina, MD, Albert Oriol, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Maria Victoria Mateos, Elizabeth K. O'Donnell, MD, Ravi Vij, MD MBA, Henk M. Lokhorst, MD PhD, Niels W.C.J. van de Donk, MD PhD, Chang-Ki Min, Tomer Mark, MD MSc, Ingemar Turesson, MD, PhD, Markus Hansson, MD, Heinz Ludwig, Sundar Jagannath, MD, Michel Delforge, MD PhD, Charalampia Kyriakou, MD PhD, Parameswaran Hari, MBBS, MD MRCP, Ulf-Henrik Mellqvist, MD PhD, Saad Z Usmani, MD FACP, Dominik Dytfeld, MD PhD, Ashraf Z Badros, MD, Philippe Moreau, Kihyun Kim, MD PhD, Paula Rodriguez Otero, MD, Jae Hoon Lee, MD, Chaim Shustik, MD, Daniel Waller, PhD, Wee Joo Chng, MD PhD, Shuji Ozaki, MD PhD, Je-Jung Lee, Javier de la Rubia, Hyeon Seok Eom, MD PhD, Laura Rosinol, MD PhD, Juan José Lahuerta, MD PhD, Anna Sureda, MD PhD, Jin Seok Kim, MD PhD, Brian G.M. Durie, MD

Blood (2016) 128 (22): 4414.

https://doi.org/10.1182/blood.V128.22.4414.4414

Published: 2016

Journal Articles

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Peter A. Forsberg, MD, Adriana C Rossi, MD, MSc, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, John N. Allan, MD, Ruben Niesvizky, MD, Tomer Mark, MD MSc

Blood (2016) 128 (22): 4518.

https://doi.org/10.1182/blood.V128.22.4518.4518

Published: 2016

Journal Articles

Sequencing of Proteasome Inhibitors in Patients with Multiple Myeloma

Benjamin Diamond, MD, Adriana C Rossi, MD, MSc, Roger N Pearse, MD PhD, David Jayabalan, BSMS, MSc, Arthur Perry, PA, Karen Pekle, NP, Tomer Mark, MD MSc, Ruben Niesvizky, MD

Blood (2016) 128 (22): 4522.

https://doi.org/10.1182/blood.V128.22.4522.4522

Published: 2016

Journal Articles

Patients (pts) with Renal Insufficiency (RI) and Multiple Myeloma (MM) Have Similar Outcomes after Autologous Hematopoietic Cell Transplantation (AHCT) As Those without

Anuj Mahindra, MD, Parmeswaran Hari, MD MRCP, MS, Raphael Fraser, PhD, Mingwei Fei, MS, Tomer Mark, MD, Yago Nieto, MD PhD, Anita D'Souza, MBBS, MD

Blood (2016) 128 (22): 994.

https://doi.org/10.1182/blood.V128.22.994.994

Published: 2016

Journal Articles

Post-Transplant Therapy Is More Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM)

Robert Frank Cornell, MD, Luciano J Costa, MD PhD, Adetola A. Kassim, MD MS, Racquel Inns-Shelton, MD, Amrita Krishnan, Tomer Mark, MD, Yago Nieto, MD PhD, Cristina J Gasparetto, Anita D'Souza, MBBS, MD, Parameswaran Hari, MD MRCP, MS, Mei-Jie Zhang, PhD, Jiaxing Huang, MS

Blood (2015) 126 (23): 396.

https://doi.org/10.1182/blood.V126.23.396.396

Published: 2015

Journal Articles

BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma

Adriana Rossi, Tomer Mark, David Jayabalan, Paul Christos, Faiza Zafar, Karen Pekle, Roger Pearse, Selina Chen-Kiang, Morton Coleman, Ruben Niesvizky

Blood (2013) 121 (11): 1982–1985.

https://doi.org/10.1182/blood-2012-08-448563

Published: 2013

Includes: Supplemental data

Journal Articles

Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma.

Blood (2009) 114 (22): 2868.

https://doi.org/10.1182/blood.V114.22.2868.2868

Published: 2009

Journal Articles

The Effect of Bortezomib, Cyclophosphamide, and Filgrastim On Complete Remission Rates and CD34+ Stem Cell Collections in Multiple Myeloma.

Tomer Mark, Megan C. Manco, Maureen Lane, Maureen Ward, Donna Skerrett, Scott Ely, Michael W. Schuster, Tsiporah B Shore, Roger N Pearse, Faiza Zafar, Selina Chen-Kiang, Morton Coleman, Ruben Niesvizky

Blood (2009) 114 (22): 4349.

https://doi.org/10.1182/blood.V114.22.4349.4349

Published: 2009

Journal Articles

Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) Breaks Plateau Responses Following Initial Induction Therapy in Multiple Myeloma: Results of a Phase II Pilot Study.

Megan C. Manco, Tomer Mark, David S Jayabalan, Faiza Zafar, Roger Pearse, Mary Crann, John P. Leonard, Selina Chen-Kiang, Morton Coleman, Ruben Niesvizky

Blood (2009) 114 (22): 2311.

https://doi.org/10.1182/blood.V114.22.2311.2311

Published: 2009

Journal Articles

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma.

Tomer Mark, MD, Morton Coleman, MD, David S Jayabalan, BSMS, Roger Pearse, MD/PhD, Faiza Zafar, PA, Scott Ely, MD, MPH, Megan C. Manco, Mary Crann, RN, John P. Leonard, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2009) 114 (22): 1861.

https://doi.org/10.1182/blood.V114.22.1861.1861

Published: 2009

Journal Articles

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

Ruben Niesvizky, MD, Scott Ely, MD, MPH, David S Jayabalan, Megan C. Manco, Seema Singhal, MD, Mary Crann, Rachel Courtney, Cynthia DuFresne, Keith D. Wilner, PhD, Isan Chen, MD, Tomer Mark, MD, John P. Leonard, MD, Morton Coleman, MD, Maurizio DiLiberto, PhD, Xiangao Huang, PhD, Selina Chen-Kiang, PhD

Blood (2009) 114 (22): 1877.

https://doi.org/10.1182/blood.V114.22.1877.1877

Published: 2009

Journal Articles

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Blood (2008) 111 (3): 1101–1109.

https://doi.org/10.1182/blood-2007-05-090258

Published: 2008

Includes: Supplemental data

Journal Articles

Atypical Serum Immunofixation Pattern (ASIP) Development during Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission.

Tomer Mark, MD, David Jayabalan, Roger N. Pearse, MD/PhD, Y. Lynn Wang, PhD, Richard Lent, MD, Paul J. Christos, MPH, Joong W. Lee, PhD, Yashpal P. Agrawal, MD/PhD, Susan Matthews, PhD, Scott Ely, MD, Madhu Mazumdar, PhD, Ethel Cesarman, MD, April Rambo, RN, John P. Leonard, MD, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2007) 110 (11): 2737.

https://doi.org/10.1182/blood.V110.11.2737.2737

Published: 2007

Journal Articles

Cyclophosphamide Overcomes the Suppressive Effect of LenalidomideTherapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.

Tomer Mark, MD, David Jayabalan, Roger N. Pearse, MD/PhD, Jessica Stern, Jessica Furst, April Rambo, RN, John Harpel, MD/PhD, Tsiporah Shore, MD, Michael Schuster, MD, John P. Leonard, MD, Paul J. Christos, MPH, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2007) 110 (11): 3024.

https://doi.org/10.1182/blood.V110.11.3024.3024

Published: 2007

NARROW

Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Selinexor Disrupts Epigenetic Programing and Modulates Immunogenicity in Multiple Myeloma

Real World Observational Study Using Clonoseq® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Sequencing of Proteasome Inhibitors in Patients with Multiple Myeloma

Patients (pts) with Renal Insufficiency (RI) and Multiple Myeloma (MM) Have Similar Outcomes after Autologous Hematopoietic Cell Transplantation (AHCT) As Those without

Post-Transplant Therapy Is More Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM)

BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma

Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma.

The Effect of Bortezomib, Cyclophosphamide, and Filgrastim On Complete Remission Rates and CD34+ Stem Cell Collections in Multiple Myeloma.

Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) Breaks Plateau Responses Following Initial Induction Therapy in Multiple Myeloma: Results of a Phase II Pilot Study.

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma.

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Atypical Serum Immunofixation Pattern (ASIP) Development during Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission.

Cyclophosphamide Overcomes the Suppressive Effect of LenalidomideTherapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only